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Abstract
Background: Decrease in lacrimal gland secretory function is related to age-induced dry eye disease. Lactoferrin, the main
glycoprotein component of tears, has multiple functions, including anti-inflammatory effects and the promotion of cell
growth. We investigated how oral administration of lactoferrin affects age-related lacrimal dysfunction.
Methods and Findings: Twelve-month-old male C57BL/6Cr Slc mice were randomly divided into a control fed group and an
oral lactoferrin treatment group. Tear function was measured at a 6-month time-point. After euthanasia, the lacrimal glands
were subjected to histological examination with 8-hydroxy-29-deoxyguanosine (8-OHdG) antibodies, and serum
concentrations of 8-OHdG and hexanoyl-lysine adduct (HEL) were evaluated. Additionally, monocyte chemotactic
protein-1(MCP-1) and tumor necrosis factor-a (TNF-a) gene expression levels were determined by real-time PCR. The volume
of tear secretion was significantly larger in the treated group than in the control. Lactoferrin administration reduced
inflammatory cell infiltration and the MCP-1 and TNF-a expression levels. Serum concentrations of 8-OHdG and HEL in the
lactoferrin group were lower than those in the control group and were associated with attenuated 8-OHdG immunostaining
of the lacrimal glands.
Conclusion: Oral lactoferrin administration preserves lacrimal gland function in aged mice by attenuating oxidative damage
and suppressing subsequent gland inflammation.
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Introduction
Lactoferrin (LF) is an iron-binding glycoprotein present in
serum and exocrine secretions [1–3]. LF suppresses inflammation,
promotes cell growth and DNA synthesis, and exhibits anti-
angiogenic and anti-tumorigenic properties [1–6]. Moreover,
various physiological qualities, such as anti-oxidative and anti-
carcinogenic bioactivities, have been attributed to LF [1–3,7].
Oxidative stress initiates a lipid peroxidation chain reaction,
thereby disrupting membranes and organelles, as well as causing
protein degradation, DNA breakage, and generating mutagenic
l e s i o n ss u c ha s8 - h y d r o x y - 2 9-deoxyguanosine (8-OHdG) [8–10],
which is a reliable marker of reactive oxygen species (ROS)-induced
DNA modification. The resulting oxidative damage could contribute
to the pathologic processes in various diseases, including cancer. In a
recent study, Tsubota et al. demonstrated that bovine LF inhibits liver
mitochondrial 8-OHdG formation in Long-Evans Cinnamon rats [6].
Tear LF levels have been reported to be an indicator of lacrimal
secretory function [11]. LF concentration in tears has been reported
to decrease in dry eye patients [11,12]. Tear secretion decrease
gradually over the age of 40 [13], and LF concentration is also
decreasing with age [13,14] and tear LF originates from lacrimal
gland acinar cells[15,16]. Therefore, it is reasonable that a LF
decrease would have some relation to lacrimal gland function.
While Shimmura et al. reported a protective effect of LF against
oxidative cellular damage in cultured corneal epithelial cells [17], our
previous studyrevealed a correlation between lacrimal gland secretory
function and age-induced dry eye disease in rats, which may stem
from oxidative stress [18]. Although the in vivo metabolism of LF
remains unclear, these findings led us to hypothesize that LF
administration may result in a protective effect on lacrimal glands.
Therefore, we investigated whether orally administered LF is
effective in preventing lacrimal dysfunction and whether this effect
is related to the antioxidative properties of LF.
Materials and Methods
Experimental protocol
All procedures undertaken in the present study conformed to
the principles outlined in the Guide for the Care and Use of Laboratory
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33148Animals published by the USA National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and were approved by the
Institutional Animal Care and Use Committee of Keio University
School of Medicine (permission No. 08067). All procedures were
performed according to the ARVO statement for the Use of
Animals in Ophthalmic and Vision Research.
Ten-month-old male C57BL/6Cr Slc mice were obtained from
Tokyo Metropolitan Institute of Gerontology (Tokyo, Japan). The
mice were housed in individual cages and fed ad libitum with
powdered AIN-93G (Oriental Yeast Co., Tokyo, Japan). After a 2-
month weaning period, 1-year-old mice were randomly divided
into 2 groups. The control group (CTL) continued to be fed with
the control diet (powdered AIN-93G) for the next 6 months, while
the LF group was fed with the experimental diet formulated by
adding 2% LF to the control diet (2% enteric-coatedbovine LF in
food weight; NRL Pharma, Kawasaki, Japan). We determined the
dose of 2% and duration of6month, following with the previous
reports [6,19,20]. The animals were maintained on a 12-h light/
dark cycle in an atmosphere-controlled room. Body weight of all
individuals was recorded weekly. Total food intake was also
recorded every week, and the daily food intake was calculated.
Lacrimal gland weights were measured at 6 months, and serum
samples were collected for biochemical analysis by auto-mated
analyzer (HITACHI 7180 Clinical Analyzer).
Tear secretion test (cotton thread test)
A phenol red-impregnated thread was placed on the temporal
side of the lower eyelid margin for 30 seconds. The length of the
moistened fragment was measured.
Sample preparation
Mice were dissected after anesthetization. The lacrimal glands
and conjunctiva were quickly removed under refrigeration (4uC).
For real-time PCR, samples were immediately frozen in liquid
nitrogen and kept at 280uC until tested. For histopathological
analysis, samples were immediately embedded in an optimal
cutting temperature compound (Tissue-Tek; Miles Inc., Elkhart,
IN) and kept at 280uC until analysis.
Histopathological examination
The lacrimal gland specimens were cut into 5-mm sections,
stained with hematoxylin and eosin, and subsequently examined
under a light microscope. In immunostaining for 8-hydroxy-29-
deoxyguanosine (8-OHdG), the specimens were blocked with
normal horse serum; the sections were layered for diluted mouse
anti-8-OHdG monoclonal antibody (Japan Institute for the
Control of Aging [JaICA], Fukuroi, Japan). Antibody binding
was detected with a horse anti-mouse IgG ABC kit (Vector
Laboratories INC, Burlingame, CA) used according to the
manufacturer’s protocol, or sections were further treated with
FITC-conjugated secondary antibodies (Jackson ImmunoRe-
search, West Grove, PA). Immunostaining for CD45, the
specimens were incubated with anti-CD45 antibody (1:100;
eBioscience, San Diego, CA, USA). Samples were then treated
with HRP-conjugated secondary antibodies (Molecular Probes,
Carlsbad, CA). HRP-conjugated antibodies were visualized by the
addition of diaminobenzidine tetrahydroxychloride. Nucleuses
were counterstained with hematoxylin. These sections were
examined under a light or fluorescence microscope.
Table 1. Primers.
sequence bp
MCP-1 TGGTGATCCTCTTGTAGCTCTCC 23
CCACTCACCTGCTGCTACTCAT 22
TNF-a ATGAGAAGTTCCCAAATGGC 20
CTCCACTTGGTGGTTTGCTA 20
GAPDH TGTGTCCGTCGTGGATCTGA 20
CCTGCTTCACCACCTTCTTGAT 22
doi:10.1371/journal.pone.0033148.t001
Table 2. Body weight and daily food intake.
CTL group LF group
Pre-experimental body weight, (average 6 SD) (g) 43.662.9 42.963.6
Post-experimental body weight, (average 6 SD) (g) 47.464.5 48.064.3
Daily food intake, (average 6 SD) (g) 3.760.3 3.860.4
doi:10.1371/journal.pone.0033148.t002
Table 3. Serum parameters.
CTL group LF group P-value
TP (g/dL) 4.860.3 4.960.2 0.83
ALB (g/dL) 2.760.3 2.860.1 0.33
CRE (mg/dL) 0.360.3 0.460.6 0.46
Na (mEq/L) 0.360.3 0.460.6 0.46
K (mEq/L) 4.560.2 4.660.7 0.91
Cl (mEq/L) 112.663.3 114.061.2 0.16
Ca (mg/dL) 8.860.4 8.760.4 0.67
IP (mg/dL) 6.960.6 6.760.9 0.46
Mg (mg/dL) 2.960.2 2.760.1 0.2
Fe (mg/dL) 118.0650.0 142.868.6 0.75
UIBC (mg/dL) 273.8661.5 192.8613.2 0.01*
TIBC (mg/dL) 391.8636.8 335.6617.7 0.02*
AST (IU/L) 147.6663.9 111.2649.2 0.46
ALT (IU/L) 124.4672.0 61.0627.1 0.29
LDH (IU/L) 882.06130.9 650.06367.2 0.46
AMY (IU/L) 2597.86490.3 3181.86382.3 0.07
T-CHO (mg/dL) 158.4638.9 152.8625.2 0.75
F-CHO (mg/dL) 36.668.2 37.466.0 0.91
E-CHO (mg/dL) 121.8630.6 115.4619.2 0.75
E/T (%) 76.860.8 75.660.5 0.03*
TG (mg/dL) 25.862.2 24.064.6 0.91
PL (mg/dL) 263.2651.9 262.0636.2 0.91
NEFA (mEq/L) 503.2643.5 315.6686.5 0.009**
LDL-C (mg/dL) 17.665.4 9.662.3 0.03*
HDL-C (mg/dL) 65.4613.2 71.269.5 0.46
T-BIL (mg/dL) 0.160.0 0.160.0 0.45
TL (mg/dL) 390.6688.5 380.4659.2 0.75
GLU (mg/dL) 193.0654.9 200.8630.9 0.91
*p,0.05.
doi:10.1371/journal.pone.0033148.t003
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A portion of lacrimal gland tissue was immediately fixed with
2.5% glutaraldehyde and subjected to the electron microscopic
examination, as described previously [21]. One-micrometer-thick
sections were stained with methylene blue, and the portions of
interest were thin-sectioned and examined with an electron
microscope (1200 EXII; JEOL, Tokyo, Japan).
Measurement of 8-OHdG and HEL concentrations in
serum
The levels of 8-OHdG and hexanoyl-lysine adduct (HEL) in the
serum were measured with highly sensitive 8-OHdG Check
ELISA and HEL ELISA (Japan Institute for the Control of Aging,
Fukuroi, Japan) according to the manufacturer’s protocol.
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated using TRIzol (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions and treated with
DNase. RNA (1 mg) was used for reverse transcription (RT).
Diluted cDNA (506) was used for quantitative PCR (qPCR). The
qPCR reactions were performed using the Light-Cycler System
(Roche Applied Science, Penzberg, Germany) and the qPCR
Supermix (Qiagen, Hilden, Germany) with primers (summarized
in Table 1) for the amplification of monocyte chemotactic protein-
1(MCP-1) and tumor necrosis factor-a (TNF-a) genes as
inflammation markers, and the GAPDH housekeeping gene.
Statistical analysis
Statistical analysis was performed using a commercially
available software package (Excel toukei, Social Survey Research
Information Co., Ltd., Tokyo, Japan). The two-tailed Student’s t-
test was used for all analyses. Statistical significance was
established at P,0.05.
Results
Body weight and serum parameters
No mice died throughout the experiment (total number of mice
is 20). No significant difference in pre- and post-experimental body
weight was observed between the CTL and the LF group (Table 2).
In the biochemical analysis of the serum, unsaturated iron binding
capacity (UIBC) and total iron binding capacity (TIBC), as well as
the levels of non-esterified fatty acids (NEFA) and low density
lipoprotein cholesterol (LDL-C) were significantly lower in the LF
group than in the CTL group. Other biochemical parameters
obtained are summarized in Table 3.
Tear secretion
At the 6-month time-point of the experiment, the tear volume
measured by the cotton thread test was significantly larger in the
LF group (average 6 SD, 18.864.8 mm) than in the CTL group
(average 6 SD, 10.764.8 mm) (Figure 1A, p,0.01). No
significant difference was found in the lacrimal gland weight
(average 6 SD, CTL: 18.665.0 mg, LF: 18.162.7 mg) between
the 2 groups (Figure 1B). The tear secretion value corrected by
lacrimal gland weight at the 6-month time-point was significantly
larger in the LF group than in the CTL group (Figure 1C).
Inflammatory changes and oxidative stress
To identify the morphological changes induced by LF in the
lacrimal gland, histological assessment was performed. Hematox-
ylin and eosin staining of lacrimal glands showed that inflamma-
tory cell infiltration was reduced in mice treated with LF, as
compared to the CTL (Figure 2A–D). Immunostainings against
CD45 also revealed weaker expression in the LF group than the
CTL (Figure 2E and F). Electron microscopy of the acinar
epithelial cells showed abnormal and disoriented vesicles in the
control animal samples, whereas uniform vesicles were observed in
the apical area of their LF counterparts (Figure 2G and H).
Electron microscopy investigation also revealed that the rough
endoplasmic reticulum architecture was better maintained in the
LF group than the CTL (Figure 2C and D). Moreover, overall
MCP-1 and TNF-a gene expression levels were lower in the LF
experimental group (Figure 3). We next examined oxidative stress
markers in the lacrimal glands. Immunohistochemistry of the
lacrimal glands showed positive staining for 8-OHdG around the
duct and acinar cells in the CTL group. In contrast, while the
lacrimal gland tissues of the LF group showed positive staining in
Figure 1. Tear secretion volume. A. Time course of the tear secretion. B. Lacrimal gland weight. C. Tear secretion corrected by lacrimal gland
weight at 6 months. The volume of tear secretion was significantly larger in the lactoferrin (LF) group compared to the control (CTL) group. *p,0.01,
N=10, average 6 standard error of mean).
doi:10.1371/journal.pone.0033148.g001
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(Figure 4). Subsequently, we applied our real-time PCR protocol
to the conjunctiva samples in order to check the ocular surface
status. MCP-1 and TNF-a expression levels tended to be lower in
the LF group than in the CTL group (Figure 5) although no
statistical significance was shown. We further performed ELISA
assays for 8-OHdG and HEL in the serum. The concentration of
8-OHdG was significantly lower in the LF group than in the CTL
group, and HEL concentrations showed the same tendency
(Figure 6).
Discussion
In this study, dietary LF seemed to provide an efficient
treatment alternative to improve tear secretion in aged mice.
Previously, Dogru et al. had demonstrated that oral administration
of LF for 1 month improved tear stability and the ocular surface
epithelium condition in dry eye patients with Sjo ¨gren syndrome
[22]. This report clearly supports our results. However, while the
previous study indicated the LF-induced increase in goblet cell
density, we did not observe any differences in expression of goblet
cell-related genes (mucin1, mucin4, mucin5AC, and SAM pointed
domain containing ets transcription factor) between the control
and the LF experimental group (data not shown). Further
investigation of LF-containing eye drops is necessary to confirm
their presumed goblet cell increasing effect [23,24] and the
consequent improvement in the ocular surface epithelium
condition [17,25,26].
Dogru et al. revealed ocular surface condition improvement and
tendency of increasing lacrimal gland secretion after 1month, but
there was no significant difference. [22]. They included the severe
Sjo ¨gren syndrome patients without symptomatic and objective
improvement despite existing treatment, and their lacrimal glands
would be damaged too severely to restore function by LF
administration. When they continued to take oral LF, they might
have improvement in tear secretion; we have detected a significant
increase in tear volume after a 6-month intake of LF in mice. This
may be partially explained by the difference in the intervention
periods or the diversity of species. Furthermore, this study used
aged mice, which suffered milder inflammation and less tissue
damage than Sjo ¨gren syndrome patients. Because of the severity of
tissue damage in Sjogren syndrome patients, LF reduced
inflammation but couldn’t improve tear secretion in 1 month.
However there is a possibility that 6month administration could
increase the tear volume for mice experimented upon in this study.
Taken together, both human and mice experiments revealed LF
supplementation was safe and effective therapy for lacrimal gland
dysfunction, so we would use LF to add to the existing treatment
for Sjo ¨gren syndrome patients or as a preventative the age-related
decline of lacrimal gland function.
LF receptors are present in human nerve tissues and are
upregulated with neural damage [27]. Bovine LF administration
has been reported to stimulate nerve growth factor secretion and
aid neural healing in mice; this may explain the improvement in
tear production observed in this study [27]. While reflex tear
secretion is disrupted by aging [28–30], LF may protect nerves to
maintain lacrimal gland secretory function.
Our real-time PCR investigation revealed the suppression of
lacrimal gland inflammation. In vivo kinetics of LF has not been
clarified completely. However, LF is known as remarkably
resistant to proteolytic degradation including trypsin and chymo-
trypsin [31]. and when LF solution was administrated, immuno-
reactive LF was able to be detected in various tissues including
mesenteric fat tissue, liver, renal and brain [32,33]. furthermore,
recent investigation demonstrated LF is transported from the small
intestine into the lymph ducts and reaches tissues via lymphatic
Figure 2. Morphological changes in lacrimal glands. Hematoxylin-eosin staining of control (A, C) and lactoferrin groups (B, D). CD45
immunostaining of lacrimal glands in the control group (E) and the lactoferrin group (F) Organelle morphology of control (G) and lactoferrin groups
(H) examined by transmission electron microscope. Scale bar indicated 100 mm (A–F) and 2 mm (G, H).
doi:10.1371/journal.pone.0033148.g002
Figure 3. Gene expression analysis in lacrimal glands. A. Tumor necrosis factor-a (TNF-a). p=0.06, N=10, average 6 standard error of mean
(SE). B. Monocyte chemotactic protein-1 (MCP-1). *p=0.01, N=10, average 6 SE. MCP-1 and TNF-a expression in the lactoferrin (LF) group were lower
than the control (CTL) group.
doi:10.1371/journal.pone.0033148.g003
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tered LF may increase the concentration of LF in the ocular
surface, we examined the RNA expression for conjunctival
inflammatory cytokines. Indeed, the expression of inflammation-
related genes (MCP-1 and TNF-a) decreased in the conjunctivae
of the LF-treated group (Figures 3 and 5). LF can directly inhibit
the production of several cytokines, including TNF-a and
interleukin 1b, via receptor-mediated signaling pathways [4,5].
For example, in rat adjuvant-induced arthritis, LF suppresses
inflammation by downregulating TNF-a and upregulating inter-
leukin 10 [5].
Several previous reports have revealed that aging induces
aggregation of inflammatory cells in lacrimal glands [18,34]. LF
prevents inflammatory cell infiltration, which may be related to
oxidative stress, in aged mice. We previously reported that calorie
restriction prevents decline in lacrimal gland function and
morphological changes in middle-aged rats, which may also be
associated with the reduction in oxidative stress and inflammation
[18].Aging has been recognized, in part, as a result of
accumulation of oxidative stress, generated continuously during
the course of metabolic processes. Thus, the observed reduction in
oxidative stress markers in the serum of the LF-treated group
suggests that LF has similar action to calorie restriction.
Furthermore, recently, our research group revealed that ROS
induced lacrimal gland dysfunction using Superoxide dismutase 2
knockout mice and smoking rats [35]. It is plausible that LF
preserves lacrimal functions by attenuating oxidative damage in
the lacrimal glands, which is further supported by previously
documented anti-oxidative effects of LF in the liver [6].
In accord with previous studies [36,37], we observed that the
non-esterified fatty acid levels decreased significantly in the LF-
treated group. Triglyceride levels showed a similar tendency,
although no marked differences could be found. Furthermore, we
observed a significant LF-induced LDL-C decrease. Since LDL-C
is recognized as the major determinant of endothelial dysfunction
and oxidative stress in patients with coronary artery disease [38],
our findings might augment the clinical benefits of intensive lipid-
lowering therapy [39].
Furthermore, we detected LF-related decline in unsaturated and
total iron-binding capacity of the serum, which is in agreement
with the iron-binding properties of LF, acting as an iron chelator
[40]. Recently, it has been shown that iron accumulation induces
Figure 5. Gene expression analysis in conjunctivae. A. TNF-a. p=0.36, N=7, average 6 standard error of mean (SE). B. MCP-1. p=0.06, N=7,
average 6 SE. MCP-1 and TNF-a expression in the lactoferrin (LF) group tended to belower than the control (CTL) group.
doi:10.1371/journal.pone.0033148.g005
Figure 4. Oxidative stress marker in lacrimal glands. 8-OHdG immunostaining of lacrimal glands in the control group (A) and the lactoferrin
group (B). Scale bar: 50 mm.
doi:10.1371/journal.pone.0033148.g004
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cardiovascular diseases [41] Moreover, an oral iron chelator has
been reported to prevent iron overload-induced retinal degener-
ation [42]. LF is capable of binding 2 atoms of iron, implicated in
the formation of free radicals [43]; thus, the chelating properties of
LF could further boost its therapeutic potential in reducing
oxidative stress [44,45]. In the present study, we used enteric-
coated LF, which is more efficiently absorbed in the intestine and
has superior anti-oxidative efficacy, as compared to plain LF [46].
It has been reported that apo-LF may be even more effective in
oxidative stress reduction, as it exhibits stronger iron-chelating
properties [44]. Therefore, further investigation of the superior
anti-oxidative characteristics of apo-LF is needed.
Lacrimal acinar cells synthesize and secrete proteins into the
tear fluid [47,48]. These include lysozyme, LF, lipocalin, and
secretory IgA. While diminished lipocalin secretion has been found
in patients with seborrheic blepharitis and meibomian gland
dysfunction, a decrease in LF discharge has been associated with
Sjo ¨gren and Stevens-Johnson syndromes [49,50]. Tear proteins
themselves can act as regulators of tear secretion [51]. Thus, LF, in
addition to reducing oxidative stress, may improve tear secretion
directly. Further investigations are needed to clarify this
assumption.
Further, as described above, LF can directly inhibit the
production of several inflammatory-related cytokines [4,5],
increase goblet cells [23,24], therefore, not only administration
but the effects of topical LF, and apo-LF which have a superior
anti-oxidative characteristics are needed.
In summary, LF may attenuate oxidative stress damage and
suppress inflammatory mediators in the lacrimal glands, as well as
preserve the lacrimal gland function. Although the detailed
mechanisms remain to be clarified, we believe that the effect of
LF on tear secretion is a combination of its direct impact on the
lacrimal glands and the overall improvement in body metabolism.
Thus, the use of LF as a nutritional supplement may be a novel
and safe treatment alternative for patients with dry eye syndrome.
It could also prove beneficial in the therapy of other age-related
diseases. To date, we have focused on highly specific, topical
treatment options for dry eye diseases, namely eye drops. Now, we
believe it is crucial to embrace a more universal approach for those
diseases such as LF supplementation as this study demonstrates.
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